



PATIENT NAME: PRAVEEN NAVARIA

CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : **0251WB002103**

PATIENT ID : PRAVM250286251 CLIENT PATIENT ID: 012302250042

ABHA NO :

AGE/SEX :37 Years Male
DRAWN :25/02/2023 09:43:00
RECEIVED :25/02/2023 12:21:52

RECEIVED : 25/02/2023 12:21:52 REPORTED :25/02/2023 16:38:12

Test Report Status Preliminary Results Biological Reference Interval Units

н	AEMATOLOGY - CBC		
MEDI WHEEL FULL BODY HEALTH CHECK UP BI	LOW 40 MALE		
BLOOD COUNTS,EDTA WHOLE BLOOD			
HEMOGLOBIN (HB) METHOD: CYANIDE FREE DETERMINATION	14.5	13.0 - 17.0	g/dL
RED BLOOD CELL (RBC) COUNT METHOD: ELECTRICAL IMPEDANCE	5.00	4.5 - 5.5	mi l /μL
WHITE BLOOD CELL (WBC) COUNT METHOD: ELECTRICAL IMPEDANCE	10.00	4.0 - 10.0	thou/µL
PLATELET COUNT METHOD: ELECTRONIC IMPEDANCE	166	150 - 410	thou/μL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV) METHOD: CALCULATED PARAMETER	42.3	40 - 50	%
MEAN CORPUSCULAR VOLUME (MCV) METHOD: CALCULATED PARAMETER	85.0	83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD: CALCULATED PARAMETER	28.9	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD: CALCULATED PARAMETER	34.2	31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW) METHOD: CALCULATED PARAMETER	13.8	11.6 - 14.0	%
MENTZER INDEX	17.0		
MEAN PLATELET VOLUME (MPV) METHOD: CALCULATED PARAMETER	11.8 High	6.8 - 10.9	fL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	61	40 - 80	%
LYMPHOCYTES METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	29	20 - 40	%
MONOCYTES METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	05	2 - 10	%
EOSINOPHILS METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	05	1 - 6	%

Dr. Akanaha I

Dr. Akansha Jain Consultant Pathologist





Page 1 Of 13











PATIENT NAME: PRAVEEN NAVARIA

CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WB002103

PATIENT ID : PRAVM250286251 CLIENT PATIENT ID: 012302250042

ABHA NO

AGE/SEX :37 Years Male :25/02/2023 09:43:00 DRAWN RECEIVED : 25/02/2023 12:21:52 REPORTED :25/02/2023 16:38:12

Test Report Status <u>Preliminary</u>	Results	Biological Reference Interval Units			
			24		
BASOPHILS METHOD: IMPEDANCE WITH HYDRO FOCUS AND MICROSCOPY	00	0 - 2	%		
ABSOLUTE NEUTROPHIL COUNT METHOD: CALCULATED PARAMETER	6.1	2.0 - 7.0	thou/μL		
ABSOLUTE LYMPHOCYTE COUNT METHOD: CALCULATED PARAMETER	2.9	1.0 - 3.0	thou/μL		
ABSOLUTE MONOCYTE COUNT METHOD: CALCULATED PARAMETER	0.5	0.2 - 1.0	thou/μL		
ABSOLUTE EOSINOPHIL COUNT METHOD: CALCULATED PARAMETER	0.5	0.02 - 0.50	thou/μL		
ABSOLUTE BASOPHIL COUNT	0 Low	0.02 - 0.10	thou/µL		
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	2.1				

Interpretation(s)
BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Akansha Jain **Consultant Pathologist** Page 2 Of 13













REF. DOCTOR: SELF **PATIENT NAME: PRAVEEN NAVARIA**

CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WB002103 PATIENT ID : PRAVM250286251

CLIENT PATIENT ID: 012302250042

ABHA NO

AGE/SEX :37 Years Male DRAWN :25/02/2023 09:43:00 RECEIVED: 25/02/2023 12:21:52

REPORTED :25/02/2023 16:38:12

Biological Reference Interval **Test Report Status** Results **Preliminary** Units

HAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

E.S.R 0 - 14mm at 1 hr

METHOD: AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)"

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays' fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. **TEST INTERPRETATION**

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging,

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. Decreased in: Polycythermia vera, Sickle cell anemia

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia False Decreased: Poikilocytosis,(SickleCells,spherocytes),Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

Dr. Akansha Jain Consultant Pathologist Page 3 Of 13













PATIENT NAME: PRAVEEN NAVARIA REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WB002103 PATIENT ID : PRAVM250286251

CLIENT PATIENT ID: 012302250042

AGE/SEX :37 Years Male DRAWN :25/02/2023 09:43:00 RECEIVED : 25/02/2023 12:21:52

REPORTED :25/02/2023 16:38:12

Test Report Status Results **Biological Reference Interval Units Preliminary**

ABHA NO

IMMUNOHAEMATOLOGY

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE O

METHOD: TUBE AGGLUTINATION

POSITIVE RH TYPE

METHOD: TUBE AGGLUTINATION

Interpretation(s)

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.'

The test is performed by both forward as well as reverse grouping methods.

Dr. Akansha Jain **Consultant Pathologist**



Page 4 Of 13









PATIENT NAME: PRAVEEN NAVARIA REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : **0251WB002103**PATIENT ID : PRAVM250286251

CLIENT PATIENT ID: 012302250042

ABHA NO :

AGE/SEX :37 Years Male
DRAWN :25/02/2023 09:43:00
RECEIVED :25/02/2023 12:21:52
REPORTED :25/02/2023 16:38:12

Test Report Status Preliminary Results Biological Reference Interval Units

	BIOCHEMISTRY		
MEDI WHEEL FULL BODY HEALTH CHECK UP I	BELOW 40 MALE		
GLUCOSE FASTING, FLUORIDE PLASMA			
FBS (FASTING BLOOD SUGAR) METHOD: GLUCOSE OXIDASE	92	74 - 99	mg/dL
GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA BLOOD	WHOLE		
HBA1C	5.5	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 Therapeutic goals: < 7.0 Action suggested : > 8.0 (ADA Guideline 2021)	%
METHOD: HIGH PERFORMANCE LIQUID CHROMATOGRAPHY (HPI	,		
ESTIMATED AVERAGE GLUCOSE(EAG)	111.2	< 116.0	mg/dL
METHOD: CALCULATED PARAMETER			
GLUCOSE, POST-PRANDIAL, PLASMA			
PPBS(POST PRANDIAL BLOOD SUGAR) METHOD: GLUCOSE OXIDASE	135	70 - 140	mg/dL
LIPID PROFILE, SERUM			
CHOLESTEROL, TOTAL	148	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL
METHOD: CHOLESTEROL OXIDASE			
TRIGLYCERIDES	58	< 150 Normal 150 - 199 Borderline High 200 - 499 High >/=500 Very High	mg/dL
METHOD: LIPASE/GPO-PAP NO CORRECTION			
HDL CHOLESTEROL	40	< 40 Low >/=60 High	mg/dL
METHOD: DIRECT CLEARANCE METHOD			

Dr. Akansha Jain Consultant Pathologist





Page 5 Of 13











PATIENT NAME: PRAVEEN NAVARIA

CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : **0251WB002103**PATIENT ID : PRAVM250286251

CLIENT PATIENT ID: 012302250042

ABHA NO :

AGE/SEX :37 Years Male
DRAWN :25/02/2023 09:43:00
RECEIVED :25/02/2023 12:21:52
REPORTED :25/02/2023 16:38:12

	<u> </u>	<u> </u>	
Test Report Status <u>Preliminary</u>	Results	Biological Reference Interva	I Units
CHOLESTEROL LDL	97	< 100 Optimal 100 - 129 Near optimal/ above optima 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL
NON HDL CHOLESTEROL	108	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
METHOD: CALCULATED PARAMETER		,	
VERY LOW DENSITY LIPOPROTEIN	11.6	= 30.0</td <td>mg/dL</td>	mg/dL
CHOL/HDL RATIO	3.7	3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk	
LDL/HDL RATIO	2.4	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Modera Risk >6.0 High Risk	
Interpretation(s)			
LIVER FUNCTION PROFILE, SERUM			
BILIRUBIN, TOTAL METHOD: DIAZO WITH SULPHANILIC ACID	0.64	0 - 1	mg/dL
BILIRUBIN, DIRECT METHOD: DIAZO WITH SULPHANILIC ACID	0.26 High	0.00 - 0.25	mg/dL
BILIRUBIN, INDIRECT METHOD: CALCULATED PARAMETER	0.38	0.1 - 1.0	mg/dL
TOTAL PROTEIN METHOD: BIURET REACTION, END POINT	7.8	6.4 - 8.2	g/dL
ALBUMIN	4.4	3.8 - 4.4	g/dL

Dr. Akansha Jain Consultant Pathologist



Page 6 Of 13









PATIENT NAME: PRAVEEN NAVARIA

CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : **0251WB002103**PATIENT ID : PRAVM250286251

CLIENT PATIENT ID: 012302250042

ABHA NO :

AGE/SEX :37 Years Male
DRAWN :25/02/2023 09:43:00
RECEIVED :25/02/2023 12:21:52
REPORTED :25/02/2023 16:38:12

	i	<u> </u>				
Test Report Status <u>Preliminary</u>	<u>r</u> Results	Biological Referenc	e Interval Units			
METHOD: BROMOCRESOL GREEN						
GLOBULIN	3.4	2.0 - 4.1	g/dL			
METHOD: CALCULATED PARAMETER						
ALBUMIN/GLOBULIN RATIO METHOD: CALCULATED PARAMETER	1.3	1.0 - 2.1	RATIO			
ASPARTATE AMINOTRANSFERASE (AST/SGOT) METHOD: TRIS BUFFER NO P5P IFCC / SFBC 37°	26	0 - 37	U/L			
ALANINE AMINOTRANSFERASE (A METHOD: TRIS BUFFER NO P5P IFCC / SFBC 37°	, ,	0 - 40	U/L			
ALKALINE PHOSPHATASE METHOD: AMP OPTIMISED TO IFCC 37° C	78	39 - 117	U/L			
	` '	11 - 50	U/L			
LACTATE DEHYDROGENASE	328	230 - 460	U/L			
BLOOD UREA NITROGEN (BUN), SE	RUM					
BLOOD UREA NITROGEN	11	5.0 - 18.0	mg/dL			
	0.95	08-13	ma/dl			
		0.0 1.3	9, 42			
BUN/CREAT RATIO						
BUN/CREAT RATIO	11.58					
·	E 4	24 70	ma/dl			
		3.4 - 7.0	ng/ac			
·	7.8	64-83	a/dL			
METHOD : BIURET REACTION, END POINT	7.10	0.1 0.5	3, 4-			
ALBUMIN, SERUM						
ALBUMIN	4.4	3.8 - 4.4	g/dL			
METHOD: BROMOCRESOL GREEN						
GLOBULIN						
GLOBULIN	3.4	2.0 - 4.1	g/dL			
ALKALINE PHOSPHATASE 78 39 - 117 U/L METHOD: AMP OPTIMISED TO IPCC 37° C GAMMA GLUTAMYL TRANSFERASE (GGT) 17 11 - 50 U/L METHOD: GAMMA GLUTAMYL TRANSFERASE (GGT) 17 11 - 50 U/L METHOD: GAMMA GLUTAMYL TRANSFERASE (GGT) 17 11 - 50 U/L METHOD: GAMMA GLUTAMYL TRANSFERASE (GGT) 17 11 - 50 U/L METHOD: GAMMA GLUTAMYL TRANSFERASE (GGT) 17 11 - 50 U/L BLOOD UREA NITROGEN 328 230 - 460 U/L BLOOD UREA NITROGEN 11 5.0 - 18.0 mg/dL METHOD: UREASE KINETIC CREATININE, SERUM CREATININE, SERUM CREATININE 0.95 0.8 - 1.3 mg/dL METHOD: ALKALINE PICRATE NO DEPROTEINIZATION BUN/CREAT RATIO 11.58 METHOD: CALCULATE PARAMETER URIC ACID, SERUM URIC ACID 5.4 3.4 - 7.0 mg/dL METHOD: URICASE PEROXIDASE WITH ASCORBATE OXIDASE TOTAL PROTEIN, SERUM TOTAL PROTEIN, SERUM TOTAL PROTEIN, SERUM TOTAL PROTEIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN, SERUM ALBUMIN 4.4 3.8 - 4.4 g/dL METHOD: BROMOCRESOL GREEN GLOBULIN						

Dr. Akansha Jain Consultant Pathologist





Page 7 Of 13

View Details

View Report









Male

REF. DOCTOR: SELF **PATIENT NAME: PRAVEEN NAVARIA**

CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WB002103 PATIENT ID : PRAVM250286251

DRAWN :25/02/2023 09:43:00 CLIENT PATIENT ID: 012302250042 RECEIVED: 25/02/2023 12:21:52 REPORTED :25/02/2023 16:38:12 ABHA NO

AGE/SEX

:37 Years

Test Report Status <u>Preliminary</u>	ry Results Biological Reference Interval Units				
ELECTROLYTES (NA/K/CL), SERUM					
SODIUM, SERUM METHOD: ION-SELECTIVE ELECTRODE	140.7	137 - 145	mmo l /L		
POTASSIUM, SERUM METHOD: ION-SELECTIVE ELECTRODE	4.37	3.6 - 5.0	mmol/L		
CHLORIDE, SERUM METHOD: ION-SELECTIVE ELECTRODE	107.0	98 - 107	mmol/L		
Interpretation(s)					

Interpretation(s)
GLUCOSE FASTING,FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine.

Increased in

Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides. **Decreased in**

Pancreatic islet cell disease with increased insulin,insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia), Drugs-insulin, ethanol, propranolol; sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-Used For:

- 1.Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2.Diagnosing diabetes.
 3.Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range. 1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

- 2. eAG gives an evaluation of blood glucose levels for the last couple of months. 3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :

I.Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

II. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.

III. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates

addiction are reported to interfere with some assay methods, falsely increasing results. IV.Interference of hemoglobinopathies in HbA1c estimation is seen in

a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy
GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin

treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give

Dr. Akansha Jain **Consultant Pathologist** Page 8 Of 13





View Report



SRL Ltd









REF. DOCTOR: SELF **PATIENT NAME: PRAVEEN NAVARIA**

CODE/NAME & ADDRESS: C000049066 SRL JAIPUR WELLNESS CORPORATE WALK IN AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100

ACCESSION NO: 0251WB002103 PATIENT ID : PRAVM250286251 CLIENT PATIENT ID: 012302250042

ABHA NO

AGE/SEX :37 Years Male DRAWN :25/02/2023 09:43:00 RECEIVED: 25/02/2023 12:21:52

REPORTED :25/02/2023 16:38:12

Test Report Status Results Biological Reference Interval Units **Preliminary**

yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health AST levels increase during acute hepatitis, sometimes due to a viral infection, is chemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget''''s disease,Rickets,Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia,Malnutrition,Protein deficiency,Wilson'''s disease.GGT is an enzyme found in cell membranes of many tissues mainly in the liver,kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom'''s disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol,

Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)
Causes of decreased level include Liver disease, SIADH.
CREATININE, SERUM-Higher than normal level may be due to:

Blockage in the urinary tract

- Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
 Loss of body fluid (dehydration)
- Muscle problems, such as breakdown of muscle fibers
- Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

- Myasthenia Gravis
- Muscular dystrophy

URIC ACID, SERUM-Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic

Causes of decreased levels-Low Zinc intake.OCP.Multiple Sclerosis

TOTAL PROTEIN, SERUM-Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom""""""" disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc.

Dr. Akansha Jain Consultant Pathologist Page 9 Of 13





View Report











PATIENT NAME: PRAVEEN NAVARIA REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WB002103**PATIENT ID: PRAVM250286251

CLIENT PATIENT ID: 012302250042

ABHA NO :

AGE/SEX : 37 Years Male
DRAWN : 25/02/2023 09:43:00
RECEIVED : 25/02/2023 12:21:52

REPORTED :25/02/2023 16:38:12

Test Report Status <u>Preliminary</u> Results Biological Reference Interval Units

CLINICAL PATH - URINALYSIS

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

PHYSICAL EXAMINATION, URINE

COLOR YELLOWISH

METHOD: GROSS EXAMINATION

APPEARANCE SLIGHTLY HAZY

METHOD: GROSS EXAMINATION

CHEMICAL EXAMINATION, URINE

PH 5.5 4.7 - 7.5

METHOD: DOUBLE INDICATOR PRINCIPLE

SPECIFIC GRAVITY 1.020 1.003 - 1.035

METHOD: IONIC CONCENTRATION METHOD

PROTEIN **DETECTED (TRACE)** NOT DETECTED

METHOD: PROTEIN ERROR OF INDICATORS WITH REFLECTANCE

GLUCOSE NOT DETECTED NOT DETECTED

METHOD : GLUCOSE OXIDASE PEROXIDASE / BENEDICTS

KETONES NOT DETECTED NOT DETECTED

 ${\tt METHOD: SODIUM\ NITROPRUSSIDE\ REACTION}$

BLOOD NOT DETECTED NOT DETECTED

METHOD: PEROCIDASE ANTI PEROXIDASE

BILIRUBIN

NOT DETECTED

NOT DETECTED

METHOD : DIPSTICK

UROBILINOGEN NORMAL NORMAL

METHOD: EHRLICH REACTION REFLECTANCE

NITRITE NOT DETECTED NOT DETECTED

METHOD: NITRATE TO NITRITE CONVERSION METHOD

LEUKOCYTE ESTERASE NOT DETECTED NOT DETECTED

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS NOT DETECTED NOT DETECTED /HPF

METHOD: MICROSCOPIC EXAMINATION

METHOD: MICROSCOPIC EXAMINATION

PUS CELL (WBC'S) 2-3 0-5 /HPF

METHOD: DIPSTICK, MICROSCOPY

EPITHELIAL CELLS 0-1 0-5 /HPF

CASTS NOT DETECTED

Dr. Akansha Jain Consultant Pathologist



Page 10 Of 13











PATIENT NAME: PRAVEEN NAVARIA

CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WB002103**PATIENT ID: PRAVM250286251

CLIENT PATIENT ID: 012302250042

ABHA NO

AGE/SEX :37 Years Male
DRAWN :25/02/2023 09:43:00
RECEIVED :25/02/2023 12:21:52

REPORTED :25/02/2023 16:38:12

Test Report Status <u>Preliminary</u> Results Biological Reference Interval Units

METHOD: MICROSCOPIC EXAMINATION

CRYSTALS NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

METHOD: MICROSCOPIC EXAMINATION

BACTERIA NOT DETECTED NOT DETECTED

YEAST NOT DETECTED NOT DETECTED

Interpretation(s)

Dr. Akansha Jain Consultant Pathologist



Page 11 Of 13

View Details

View Report









PATIENT NAME: PRAVEEN NAVARIA

CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO : **0251WB002103**PATIENT ID : PRAVM250286251

CLIENT PATIENT ID: 012302250042

ABHA NO :

AGE/SEX : 37 Years Male
DRAWN : 25/02/2023 09:43:00
RECEIVED : 25/02/2023 12:21:52

REPORTED :25/02/2023 16:38:12

Test Report Status Preliminary Results Biological Reference Interval Units

CLINICAL PATH - STOOL ANALYSIS

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOWE DING
PHYSICAL EXAMINATION, STOOL RESULT PENDING
CHEMICAL EXAMINATION, STOOL RESULT PENDING
MICROSCOPIC EXAMINATION, STOOL RESULT PENDING

Page 12 Of 13













PATIENT NAME: PRAVEEN NAVARIA REF. DOCTOR: SELF

CODE/NAME & ADDRESS: C000049066

SRL JAIPUR WELLNESS CORPORATE WALK IN
AAKRITI LABS PVT LTD. A-430, AGRASEN MARG

JAIPUR 302017 9314660100 ACCESSION NO: **0251WB002103**PATIENT ID: PRAVM250286251
CLIENT PATIENT ID: 012302250042

ABHA NO :

AGE/SEX : 37 Years Male
DRAWN : 25/02/2023 09:43:00
RECEIVED : 25/02/2023 12:21:52

REPORTED :25/02/2023 16:38:12

Test Report Status <u>Preliminary</u> Results Biological Reference Interval Units

SPECIALISED CHEMISTRY - HORMONE

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE

THYROID PANEL, SERUM

T3 110.69 60.0 - 181.0 ng/dL T4 9.20 4.5 - 10.9 µg/dL TSH (ULTRASENSITIVE) 4.517 0.550 - 4.780 µIU/mL

End Of Report
Please visit www.srlworld.com for related Test Information for this accession

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services.3. Result delays could occur due to unforeseen
- circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

SRL Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Dr. Akansha Jain Consultant Pathologist





Page 13 Of 13











Aakriti Labs

3 Mahatma Gandhi Marg, Gandhi Nagar Mod Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661

www.aakritilabs.com

CIN NO.: U85195RJ2004PTC019563

Name

: Mr. PRAVEEN NAVARIA

Age/Gender: 37 Y/Male

Patient ID : 012302250042

BarcodeNo:10077516

Referred By : Self

Registration No: 52736

Registered

: 25/Feb/2023 09:43AM

Analysed

: 25/Feb/2023 01:38PM

Reported Panel

: 25/Feb/2023 01:38PM : Medi Wheel (ArcoFemi

Healthcare Ltd)

USG: WHOLE ABDOMEN (Male)

LIVER

: Is normal in size, shape and echogenecity.

The IHBR and hepatic radicals are not dilated. No evidence of focal echopoor/echorich lesion seen.

Portal vein diameter and common bile duct appear normal.

GALL

: Is normal in size, shape and echotexture. Walls are smooth and

BLADDER regular with normal thickness. There is no evidence of cholelithiasis.

PANCREAS : Is normal in size, shape and echotexture. Pancreatic duct is not dilated.

:Is normal in size, shape and echogenecity. Spleenic hilum is not dilated.

KIDNEYS: Bilateral Kidneys are normal in size, shape and echotexture, corticomedullary differentiation is fair and ratio appears normal.

Pelvi calyceal system is normal. No evidence of hydronephrosis/ nephrolithiasis.

URINARY: Bladder walls are smooth, regular and normal thickness.

BLADDER : No evidence of mass or stone in bladder lumen.

PROSTATE: Is normal in size, shape and echotexture, measures: 33 x 29 x 29 mm, wt: 14 gms.

Its capsule is intact and no evidence of focal lesion.

SPECIFIC: No evidence of retroperitoneal mass or free fluid seen in peritoneal cavity. No evidence of lymphadenopathy or mass lesion in retroperitoneum. Visualized bowel loop appear normal. Great vessels appear normal.

IMPRESSION :- NORMAL STUDY.

*** End Of Report ***


Page 1 of 1

Dr. Neera Mehta M.B.B.S., D.M.R.D.

RMCNO.005807/14853









Aakriti Labs

3, Mahatma Gandhi Marg, Gandhi Nagar Mod, Tonk Road, Jaipur (Raj.) Ph.: 0141-2710661 www.aakritilabs.com CIN No. U85195RJ2004PTC019563

NAME	MR. PRAVEEN NAVARIA	AGE	37 YRS	SEX	MALE
REF BY	BOB	DATE	25/02/2023	REG NO	

ECHOCARDIOGRAM REPORT

WINDOW-	POOR	/ADEQUATE	/GOODVALVE
---------	------	-----------	------------

WINDOW- PO	OR/ADEQ	UATE	/GOC	DVALVE				
MITRAL NORMAL		TRICUSPID		NORMAL				
AORTIC		NOR	MAL		PULMONA	Table to Cartana Street Street		AL
2D/M-MOD					100000000000000000000000000000000000000			
IVSD mm	11.2			IVSS	13.3	13.3 AORTA		27.3
LVID mm	47.8			LVIS mm	29.3			32.1
LVPWD mm	12.9			LVPWS mm	12.9	EF%		60%
CHAMBERS								500 67 V 150
LA			NOR	MAL	RA		NO	RMAL
LV			NOR	MAL	RV		NO	RMAL
PERICARDIUM			NOR	MAL				OCH CHAMC
DOPPLER STU	DY MITRA	L ii				addin.		
PEAK VELOCITY			0.57/0.77		PEAK GR	PEAK GRADIANT MmHg		
MEAN VELOCIT	TY m/s				MEAN GI	MEAN GRADIANT MmHg		
MVA cm2 (PLA	NITMETER	RY)			MVA cm2	MVA cm2 (PHT)		
MR								
AORTIC					4	100		
PEAK VELOCITY m/s			1.80		PEAK GRA	ADIANT MmHg		
MEAN VELOCIT	Y m/s					RADIANT MmH		
AR				and the				
TRICUSPID							The same of the sa	
PEAK VELOCITY	m/s		0.79		PEAK GRADIANT MmHg			
MEAN VELOCIT	Y m/s		400		MEAN GRADIAN			
TR		A			PASP mmHg			
PULMONARY				VALO				
PEAK VELOCITY	m/s		1.42	VVV	PEAK GRA	ADIANT MmHg	7	
MEAN VELOCITY m/s						MEAN GRADIANT MmHg		
DD				100 Table 100 Ta	10.000000000000000000000000000000000000		0	

RVEDP mmHg

IMPRESSION

- NORMAL LV SYSTOLIC & DIASTOLIC FUNCTION
- **NO RWMA LVEF 60%**
- NORMAL RV FUNCTION
- **BORDER LINE LVH**
- NORMAL VALVULAR ECHO
- INTACT IAS / IVS
- NO THROMBUS, NO VEGETATION, NORMAL PERICARDIUM.
- **IVC NORMAL**
- CONCLUSION: BORDER LINE LVH, FAIR LV FUNCTION.

Cardiologist